# SES AI Corp: financial statements, quarterly

SES · NYSE · CIK 1819142 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ses.md) · [Financials](/companies/ses/financials.md) · [Filings](/companies/ses/filings.md) · [Insiders](/companies/ses/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ses/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | [5.8](/filings/0001819142-26-000026.md) | [3.5](/filings/0001819142-26-000045.md) | [7.1](/filings/0001819142-25-000070.md) | [4.6 d](/filings/0001819142-26-000010.md) | [6.7](/filings/0001819142-26-000026.md) | [5.1](/filings/0001819142-26-000045.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | [1.2](/filings/0001819142-26-000026.md) | [0.9](/filings/0001819142-26-000045.md) | [3.5](/filings/0001819142-25-000070.md) | [4.0 d](/filings/0001819142-26-000010.md) | [5.5](/filings/0001819142-26-000026.md) | [3.9](/filings/0001819142-26-000045.md) |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | [4.6](/filings/0001819142-26-000026.md) | [2.6](/filings/0001819142-26-000045.md) | [3.6](/filings/0001819142-25-000070.md) | [0.5 d](/filings/0001819142-26-000010.md) | [1.2](/filings/0001819142-26-000026.md) | [1.1](/filings/0001819142-26-000045.md) |
| Research and development | $m | [8.5](/filings/0001819142-24-000046.md) | [7.4 d](/filings/0001819142-25-000017.md) | [11.8](/filings/0001819142-25-000035.md) | [15.1](/filings/0001819142-25-000046.md) | [24.4](/filings/0001819142-25-000070.md) | [20.9 d](/filings/0001819142-26-000010.md) | [20.5](/filings/0001819142-26-000026.md) | [19.1](/filings/0001819142-26-000045.md) | [15.6](/filings/0001819142-25-000070.md) | [11.8 d](/filings/0001819142-26-000010.md) | [11.0](/filings/0001819142-26-000026.md) | [11.4](/filings/0001819142-26-000045.md) |
| Operating income | $m | [(19.4)](/filings/0001819142-24-000046.md) | [(17.9) d](/filings/0001819142-25-000017.md) | [(21.3)](/filings/0001819142-25-000035.md) | [(24.6)](/filings/0001819142-25-000046.md) | [(34.2)](/filings/0001819142-25-000070.md) | [(29.1) d](/filings/0001819142-26-000010.md) | [(23.3)](/filings/0001819142-26-000026.md) | [(23.0)](/filings/0001819142-26-000045.md) | [(18.6)](/filings/0001819142-25-000070.md) | [(17.7) d](/filings/0001819142-26-000010.md) | [(17.9)](/filings/0001819142-26-000026.md) | [(19.2)](/filings/0001819142-26-000045.md) |
| Income tax | $m | [0.2](/filings/0001819142-24-000046.md) | [(1.5) d](/filings/0001819142-25-000017.md) | [0.2](/filings/0001819142-25-000035.md) | [0.1](/filings/0001819142-25-000046.md) | [0.1](/filings/0001819142-25-000070.md) | [(0.2) d](/filings/0001819142-26-000010.md) | [0.0](/filings/0001819142-26-000026.md) | [0.7](/filings/0001819142-26-000045.md) | [(0.1)](/filings/0001819142-25-000070.md) | [(0.3) d](/filings/0001819142-26-000010.md) | [0.4](/filings/0001819142-26-000026.md) | [0.1](/filings/0001819142-26-000045.md) |
| Net income | $m | [(13.5)](/filings/0001819142-24-000046.md) | [(10.8) d](/filings/0001819142-25-000017.md) | [(15.6)](/filings/0001819142-25-000070.md) | [(19.9)](/filings/0001819142-25-000070.md) | [(30.2)](/filings/0001819142-25-000070.md) | [(34.5) d](/filings/0001819142-26-000010.md) | [(12.4)](/filings/0001819142-26-000026.md) | [(22.7)](/filings/0001819142-26-000045.md) | [(20.9)](/filings/0001819142-25-000070.md) | [(17.0) d](/filings/0001819142-26-000010.md) | [(12.1)](/filings/0001819142-26-000026.md) | [(17.9)](/filings/0001819142-26-000045.md) |
| Diluted EPS | $ per share | [(0.04)](/filings/0001819142-24-000046.md) | not reported | [(0.05)](/filings/0001819142-25-000035.md) | [(0.06)](/filings/0001819142-25-000046.md) | [(0.09)](/filings/0001819142-25-000070.md) | not reported | [(0.04)](/filings/0001819142-26-000026.md) | [(0.07)](/filings/0001819142-26-000045.md) | [(0.06)](/filings/0001819142-25-000070.md) | not reported | [(0.04)](/filings/0001819142-26-000026.md) | [(0.05)](/filings/0001819142-26-000045.md) |
| Basic EPS | $ per share | [(0.04)](/filings/0001819142-24-000046.md) | not reported | [(0.05)](/filings/0001819142-25-000035.md) | [(0.06)](/filings/0001819142-25-000046.md) | [(0.09)](/filings/0001819142-25-000070.md) | not reported | [(0.04)](/filings/0001819142-26-000026.md) | [(0.07)](/filings/0001819142-26-000045.md) | [(0.06)](/filings/0001819142-25-000070.md) | not reported | [(0.04)](/filings/0001819142-26-000026.md) | [(0.05)](/filings/0001819142-26-000045.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [49.9](/filings/0001819142-23-000087.md) | [85.7](/filings/0001819142-25-000017.md) | [130](/filings/0001819142-24-000025.md) | [54.8](/filings/0001819142-24-000033.md) | [66.7](/filings/0001819142-24-000046.md) | [129](/filings/0001819142-26-000010.md) | [56.1](/filings/0001819142-25-000035.md) | [11.8](/filings/0001819142-25-000046.md) | [35.3](/filings/0001819142-25-000070.md) | [29.5](/filings/0001819142-26-000045.md) | [46.9](/filings/0001819142-26-000026.md) | [64.1](/filings/0001819142-26-000045.md) |
| Current assets | $m | [352](/filings/0001819142-23-000087.md) | [349](/filings/0001819142-25-000017.md) | [327](/filings/0001819142-24-000025.md) | [310](/filings/0001819142-24-000033.md) | [291](/filings/0001819142-24-000046.md) | [277](/filings/0001819142-26-000010.md) | [256](/filings/0001819142-25-000035.md) | [243](/filings/0001819142-25-000046.md) | [230](/filings/0001819142-25-000070.md) | [216](/filings/0001819142-26-000045.md) | [201](/filings/0001819142-26-000026.md) | [186](/filings/0001819142-26-000045.md) |
| Total assets | $m | [403](/filings/0001819142-23-000087.md) | [407](/filings/0001819142-25-000017.md) | [386](/filings/0001819142-24-000025.md) | [368](/filings/0001819142-24-000033.md) | [350](/filings/0001819142-24-000046.md) | [330](/filings/0001819142-26-000010.md) | [306](/filings/0001819142-25-000035.md) | [290](/filings/0001819142-25-000046.md) | [289](/filings/0001819142-25-000070.md) | [273](/filings/0001819142-26-000045.md) | [254](/filings/0001819142-26-000026.md) | [236](/filings/0001819142-26-000045.md) |
| Current liabilities | $m | [15.8](/filings/0001819142-23-000087.md) | [20.4](/filings/0001819142-25-000017.md) | [13.9](/filings/0001819142-24-000025.md) | [14.0](/filings/0001819142-24-000033.md) | [19.1](/filings/0001819142-24-000046.md) | [22.8](/filings/0001819142-26-000010.md) | [16.4](/filings/0001819142-25-000035.md) | [19.5](/filings/0001819142-25-000046.md) | [28.0](/filings/0001819142-25-000070.md) | [24.2](/filings/0001819142-26-000045.md) | [29.2](/filings/0001819142-26-000026.md) | [28.5](/filings/0001819142-26-000045.md) |
| Total liabilities | $m | [39.5](/filings/0001819142-23-000087.md) | [47.9](/filings/0001819142-25-000017.md) | [38.5](/filings/0001819142-24-000025.md) | [36.8](/filings/0001819142-24-000033.md) | [40.6](/filings/0001819142-24-000046.md) | [51.5](/filings/0001819142-26-000010.md) | [36.1](/filings/0001819142-25-000035.md) | [41.2](/filings/0001819142-25-000046.md) | [60.6](/filings/0001819142-25-000070.md) | [57.9](/filings/0001819142-26-000045.md) | [50.3](/filings/0001819142-26-000026.md) | [49.2](/filings/0001819142-26-000045.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [1.9](/filings/0001819142-25-000070.md) | [0.8](/filings/0001819142-26-000045.md) | [0.7](/filings/0001819142-26-000026.md) | [0.4](/filings/0001819142-26-000045.md) |
| Shareholders' equity | $m | [364](/filings/0001819142-23-000087.md) | [359](/filings/0001819142-25-000017.md) | [347](/filings/0001819142-24-000025.md) | [332](/filings/0001819142-24-000033.md) | [309](/filings/0001819142-24-000046.md) | [278](/filings/0001819142-26-000010.md) | [270](/filings/0001819142-25-000035.md) | [249](/filings/0001819142-25-000046.md) | [228](/filings/0001819142-25-000070.md) | [215](/filings/0001819142-26-000045.md) | [203](/filings/0001819142-26-000026.md) | [187](/filings/0001819142-26-000045.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(13.0) d](/filings/0001819142-24-000046.md) | [(12.5) d](/filings/0001819142-25-000017.md) | [(9.0)](/filings/0001819142-25-000035.md) | [(22.1) d](/filings/0001819142-25-000046.md) | [(22.7) d](/filings/0001819142-25-000070.md) | [(12.3) d](/filings/0001819142-26-000010.md) | [(22.8)](/filings/0001819142-26-000026.md) | [(10.8) d](/filings/0001819142-26-000045.md) | [(14.3) d](/filings/0001819142-25-000070.md) | [(10.4) d](/filings/0001819142-26-000010.md) | [(19.8)](/filings/0001819142-26-000026.md) | [(13.8) d](/filings/0001819142-26-000045.md) |
| Capital expenditure | $m | [4.5 d](/filings/0001819142-24-000046.md) | [3.5 d](/filings/0001819142-25-000017.md) | [6.8](/filings/0001819142-25-000035.md) | [3.7 d](/filings/0001819142-25-000046.md) | [1.5 d](/filings/0001819142-25-000070.md) | [0.2 d](/filings/0001819142-26-000010.md) | [0.9](/filings/0001819142-26-000026.md) | [0.8 d](/filings/0001819142-26-000045.md) | [0.4 d](/filings/0001819142-25-000070.md) | [0.7 d](/filings/0001819142-26-000010.md) | [0.3](/filings/0001819142-26-000026.md) | [0.7 d](/filings/0001819142-26-000045.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0 d](/filings/0001819142-26-000010.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [312](/filings/0001819142-23-000087.md) | [313](/filings/0001819142-24-000025.md) | [315](/filings/0001819142-24-000033.md) | [316](/filings/0001819142-24-000046.md) | [319](/filings/0001819142-25-000035.md) | [321](/filings/0001819142-25-000046.md) | [322](/filings/0001819142-25-000070.md) | [329](/filings/0001819142-26-000026.md) | [332](/filings/0001819142-26-000045.md) | [331](/filings/0001819142-25-000070.md) | [333](/filings/0001819142-26-000026.md) | [336](/filings/0001819142-26-000045.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.